← Volver a resultados
Ficha bibliográfica · Consulta y acceso
Artículo

Can the GAD-7 be used to create valid, reliable, feasible and actionable outcome-focused paediatric anxiety quality measures for use across specialty and paediatric treatment settings?

Corinna Koebnick et al · BMJ Publishing Group · 2026

Acceso institucional disponible
Lectura rápida. Revisá los datos básicos del recurso y luego accedé al contenido desde el botón principal. En esta ficha solo se muestra la información necesaria para identificar la obra, citarla y abrirla.

Acceso al recurso

Entrá al contenido desde la opción principal o elegí otra fuente disponible.

Acceso principal

Acceso institucional disponible

El acceso puede requerir institución, suscripción, proxy, VPN o autenticación.
Abrir acceso

Resumen

Descripción general del contenido del recurso.

Introduction Paediatric anxiety disorders are among the most common psychiatric disorders of childhood and adolescence, affecting between 15% and 30% of youth. Rates rose sharply during the COVID-19 pandemic, and untreated anxiety is associated with impaired functioning and increased risk of depression, suicidality and substance use in adulthood. Evidence-based treatments such as cognitive-behavioural therapy and selective serotonin reuptake inhibitors are highly effective yet remain underused, while non-recommended treatments, including benzodiazepines, are often prescribed. Despite the public health burden, there are currently no endorsed outcome-focused quality measures for paediatric anxiety. Developing such measures would allow health systems and providers to track outcomes, reduce disparities and drive quality improvement.Methods and analysis This study will develop and test two complementary outcome-focused paediatric anxiety quality measures based on the seven-item Generalised Anxiety Disorder scale: (1) remission (clinically significant reduction in anxiety symptoms to below threshold) and (2) response (clinically significant improvement, even if remission is not achieved). Using electronic health record and claims data from Kaiser Permanente Northwest and Kaiser Permanente Southern California from 2017 to 2024, we will establish measure inclusion and exclusion criteria, evaluate the application of symptom weighting, test measure reliability and validity and implement casemix adjustment models. Analyses will examine disparities by race, ethnicity and social risk factors through linkage indices capturing local social determinants of health. Qualitative interviews with providers and electronic medical record vendors will be conducted to assess feasibility and usability. Measures will be prepared and submitted for endorsement by a national quality measurement body.Ethics and dissemination This study has been reviewed and approved by the institutional review boards at RTI International and Kaiser Permanente. Findings will be disseminated through peer-reviewed publications, scientific conferences, stakeholder workshops and submissions to a national quality endorsement body.

Cómo citar

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, C. K. E. (2026). Can the GAD-7 be used to create valid, reliable, feasible and actionable outcome-focused paediatric anxiety quality measures for use across specialty and paediatric treatment settings?. https://doi.org/10.1136/bmjopen-2026-119157

MLA

al, Corinna Koebnick et. "Can the GAD-7 be used to create valid, reliable, feasible and actionable outcome-focused paediatric anxiety quality measures for use across specialty and paediatric treatment settings?." 2026. https://doi.org/10.1136/bmjopen-2026-119157.

Chicago

al, Corinna Koebnick et. 2026. "Can the GAD-7 be used to create valid, reliable, feasible and actionable outcome-focused paediatric anxiety quality measures for use across specialty and paediatric treatment settings?.". https://doi.org/10.1136/bmjopen-2026-119157.

Harvard

al, C. K. E. 2026, Can the GAD-7 be used to create valid, reliable, feasible and actionable outcome-focused paediatric anxiety quality measures for use across specialty and paediatric treatment settings?, BMJ Publishing Group, available at: https://doi.org/10.1136/bmjopen-2026-119157 [Accessed 30 Jun. 2026].

Compartir e imprimir

Guardá la ficha, copiá su enlace permanente o imprimila como PDF.

Exportar referencia

Si usás un gestor bibliográfico, podés exportar el registro en los formatos más comunes.

Detalles del recurso

Información bibliográfica útil para confirmar que se trata del material correcto.

Título
Can the GAD-7 be used to create valid, reliable, feasible and actionable outcome-focused paediatric anxiety quality measures for use across specialty and paediatric treatment settings?
Autor / colaboradores
Corinna Koebnick et al
Editorial
BMJ Publishing Group
Año de publicación
2026
ISSN
2044-6055
ISSN
2044-6055
Idioma
eng
Copiado